Bengaluru is stepping up its fight against antimicrobial resistance (AMR) with a new scientific surveillance system designed to identify and monitor the spread of drug-resistant infections. Antimicrobial resistance is increasingly recognised as one of the most serious emerging public health threats globally, and this initiative aims to track its prevalence and inform treatment strategies.
What Is Antimicrobial Resistance?
Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. The World Health Organization has declared AMR a top global public health threat.
Bengaluru's Surveillance Initiative
The new surveillance system in Bengaluru will use advanced scientific methods to collect data on resistant pathogens from hospitals, laboratories, and community settings. This data will help health authorities understand which antibiotics are losing effectiveness and guide policies to preserve the power of existing drugs.
- Identification: Rapid diagnostic tests will pinpoint resistant strains early.
- Monitoring: Continuous tracking of resistance patterns across the city.
- Response: Data-driven interventions to limit spread and optimise antibiotic use.
The Karnataka government is collaborating with research institutions and global health partners to implement the programme. Experts say such surveillance is critical for India, which has high rates of antibiotic misuse and a growing burden of resistant infections.
This initiative aligns with the National Action Plan on Antimicrobial Resistance, which emphasises enhanced surveillance, infection prevention, and rational antibiotic use. The Bengaluru model could serve as a template for other Indian cities.
Residents are urged to use antibiotics only when prescribed by a qualified doctor and to complete the full course of treatment. Public awareness campaigns will accompany the surveillance rollout to educate communities about the dangers of self-medication and incomplete dosing.
The surveillance programme is expected to be fully operational within six months, with regular reports to guide clinical practice and public health policy.
